3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
6
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Endometrial Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Melanoma
2
Carcinosarcoma
2
Bile Duct Neoplasms
2
Advanced Solid Tumours
2
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour Refractory to Conventional Treatment
1
Salivary Gland Neoplasms
1
SCLC
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms by Site
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Interventions
Carboplatin
15
Pemetrexed
8
Paclitaxel
6
pembrolizumab
5
osimertinib
4
atezolizumab
4
Gemcitabine
4
Erlotinib Hydrochloride
4
entinostat
3
durvalumab
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
camrelizumab
2
apatinib
2
Vinorelbine
2
Radiosurgery
2
Nivolumab
2
Injections
2
Gefitinib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
toripalimab
1
sotorasib
1
sintilimab
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
patritumab
1
necitumumab
1
napabucasin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thoracic Neoplasms
×
ceralasertib
×
Clear all
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled